Downloads
Abstract
Background: Neoadjuvant chemotherapy for breast cancer was used to downstaging tumours to facilitate breast-conserving surgery.
Methods: A descriptive retrospective study of 93 breast cancer patients at Da Nang Oncology Hospital from January 2017 to December 2019. Patients diagnosed with locally advanced breast cancer cT2-4N03M0. Exclude cases of Ductal carcinoma in situ from breast or previously treated.
Results: an average age of 48, an average tumor size of 6.0 cm, the majority were Invasive ductal carcinoma (97.8%) and grade 2 ( 85.6%). Hormon receptor positive in 57%, HER-2 positive in 38.7% and 18.3% triple negative Breast cancer. The combination chemotherapy regimen Anthacycline and Taxane accounted for 94.7%, Trastuzumab-based regimen accounted for 25%. There was 8.3% progression of disease during neoadjuvant chemotherapy. About Surgery: Breast- conserving surgery in 20.5%, Breast reconstruction in 6.8%, Mastectomy in 71.6%, Sentinel lymph node biopsy in 4.3%. Her2 status was significantly different between the groups with and without pCR.. Endocrine receptors are negative, Ki67 is high, and Triple negative has a higher rate of pCR but not statistically significant.
Conclusion: Neoadjuvant chemotherapy helps to downstaging tumours to facilitate breast-conserving surgery. Her2 status is correlated with the rate of complete pathological response (pCR).
References
Bonadonna G. et al. (1995), “Primary chemotherapy in surgically resectable breast cancer”, CA Cancer J Clin. 45 (4), pp. 227-243..
Esserman L. J. et al. (2012), “Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657”, J Clin Oncol. 30 (26), pp. 3242-3249.
Fisher B. et al. (1997), “Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18”, J Clin Oncol. 15 (7), pp. 2483-2493..
Kaufmann M. et al. (2006), “Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update”, J Clin Oncol. 24 (12), pp. 1940-1949..
Kaufmann M. et al. (2012), “Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer”, Ann Surg Oncol. 19 (5), pp. 1508-1516..
Mathew J. et al. (2009), “Primary endocrine therapy in locally advanced breast cancers--the
Nottingham experience”, Breast Cancer Res Treat. 113 (2), pp. 403-407..
Mauri D. et al. (2005), “Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis”, J Natl Cancer Inst. 97 (3), pp. 188-194..
Perloff M. et al. (1982), “Chemotherapy before and after mastectomy in stage III breast cancer”, Arch Surg. 117 (7), pp. 879-881..
Rastogi P. et al. (2008), “Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27”, J Clin Oncol. 26 (5), pp. 778-785..
Schick P. et al. (1983), “Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer”, J Surg Oncol. 22 (4), pp. 278-282..
Smith I. C. et al. (2002), “Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel”, J Clin Oncol. 20 (6), pp. 1456-1466..
von Minckwitz G. et al. (2012), “Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes”, J Clin Oncol. 30 (15), pp. 1796-1804..
| Published | 11-01-2025 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 65 (2020) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.2020.65.14 | |
| Keywords | Hóa trị tân bổ trợ, Ung thư vú, Đáp ứng bệnh học toàn toàn (pCR), Neoadjuvant chemotherapy, Breast cancer, Pathologic complete response. |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2020 Journal of Clinical Medicine Hue Central Hospital